var data={"title":"Rocuronium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rocuronium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6922?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">see &quot;Rocuronium: Drug information&quot;</a> and <a href=\"topic.htm?path=rocuronium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rocuronium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219069\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zemuron [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219070\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Rocuronium Bromide Injection;</li>\n      <li>Zemuron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061877\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Neuromuscular Blocker Agent, Nondepolarizing</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Skeletal Muscle Relaxant, Paralytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445026\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient. In general, the onset of effect is shortened and duration is prolonged as the dose increases. The time to maximum nerve block is longest in neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tracheal intubation, surgical:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: IV: 0.45 to 0.6 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance for continued surgical relaxation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV dosing: 0.075 to 0.15 mg/kg; dosing interval as determined by monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 7 to 10 <b>mcg</b>/kg/minute (0.42 to 0.6 mg/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tracheal intubation, nonemergent:</b> IV: 0.6 to 1.2 mg/kg (Kumar 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment necessary; duration of neuromuscular blockade may vary in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage reductions may be necessary in patients with liver disease; duration of neuromuscular blockade may be prolonged due to increased volume of distribution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061870\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">see &quot;Rocuronium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient. In general, the onset of effect is shortened and duration is prolonged as the dose increases. The time to maximum nerve block is shortest in infants 1 to 3 months; the duration of relaxation is shortest in children 2 to 11 years and longest in infants. The manufacturer recommends dosing based on actual body weight in all obese patients; however, some have recommended dosing based on ideal body weight (IBW) in obese patients (Playfor 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rapid sequence intubation:</b> Children and Adolescents: IV: 0.9 to 1.2 mg/kg; <b>Note:</b> Lower doses of 0.6 mg/kg have been reported in the literature; however, some studies found this dosing resulted in prolonged time to onset, shortened duration of neuromuscular blockade and less favorable intubating conditions (Cheng 2002; Fuchs-Buder 1996; Mazurek 1998; Naguib 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tracheal intubation, surgical:</b> Infants, Children, and Adolescents: <b>Note:</b> Inhaled anesthetic agents prolong the duration of action of rocuronium; use lower end of the dosing range; dosing interval guided by monitoring with a peripheral nerve stimulator.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 0.45 to 0.6 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM (Kaplan 1999):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &ge;3 months: 1 mg/kg administered as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 1 to 6 years: 1.8 mg/kg administered as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance for continued surgical relaxation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV dosing: Infants, Children, and Adolescents: 0.075 to 0.15 mg/kg; repeat as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: Infants, Children, and Adolescents: 7 to 12 <b>mcg</b>/kg/minute (0.42 to 0.72 mg/kg/<b>hour</b>); the manufacturer recommends using  the lower end of the dosing range for infants and the upper end for children &gt;2 to &le;11 years of age; higher doses have been reported with prolonged infusions (Tobias 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rapid sequence intubation:</b> IV: 0.6 to 1.2 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Obesity: In adult patients with morbid obesity (BMI &gt;40 kg/m<sup>2</sup>), the use of 1.2 mg/kg using ideal body weight (IBW) provided a short onset of action and excellent or good intubating conditions at 60 seconds in one study (Gaszynski 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tracheal intubation:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial:</i> 0.45 to 0.6 mg/kg; administration of 0.3 mg/kg may also provide optimal conditions for tracheal intubation (Barclay 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Obesity: May use ideal body weight (IBW) for morbidly obese (BMI &gt;40 kg/m<sup>2</sup>) adult patients (Leykin 2004); onset time may be slightly delayed using IBW. The manufacturer recommends dosing based on actual body weight in all obese patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance for continued surgical relaxation:</i> 0.1 to 0.2 mg/kg; repeat as needed or a continuous infusion of 10 to 12 <b>mcg</b>/kg/minute (0.6 to 0.72 mg/kg/<b>hour</b>) only after recovery of neuromuscular function is evident; infusion rates have ranged from 4 to 16 <b>mcg</b>/kg/minute (0.24 to 0.96 mg/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Inhaled anesthetic agents prolong the duration of action of rocuronium. Use lower end of the dosing range; redosing interval guided by monitoring with a peripheral nerve stimulator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ICU paralysis (eg, facilitate mechanical ventilation) in selected adequately sedated patients</b> (Greenberg 2013; Murray 2002; Rudis 1996; Sparr 1997; Warr 2011): Initial bolus dose: 0.6 to 1 mg/kg, then a continuous IV infusion of 8 to 12 <b>mcg</b>/kg/minute (0.48 to 0.72 mg/kg/<b>hour</b>); monitor depth of blockade every 2 to 3 hours initially until stable dose, then every 8 to 12 hours; adjust rate of administration by 10% increments according to peripheral nerve stimulation response or desired clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent dosing has also been described with an initial loading dose of 50 mg followed by 25 mg given when peripheral nerve stimulation returns (Sparr 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: No dosage adjustment necessary; duration of neuromuscular blockade may vary in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage reductions may be necessary in patients with liver disease; duration of neuromuscular blockade may be prolonged due to increased volume of distribution. When rapid sequence intubation is required in adult patients with ascites, a dose on the higher end of the dosage range may be necessary to achieve adequate neuromuscular blockade.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219051\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemuron: 50 mg/5 mL (5 mL [DSC]); 100 mg/10 mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219037\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061880\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: May be administered undiluted by rapid IV injection; or further diluted and infused as a  continuous IV infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219067\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store unopened/undiluted vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. When stored at room temperature (25&deg;C [77&deg;F]), it is stable for 60 days; once opened, use within 30 days. Dilutions up to 5 mg/mL in 0.9% sodium chloride, dextrose 5% in water, 5% dextrose in sodium chloride 0.9%, or lactated Ringer's are stable for up to 24 hours at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061879\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to general anesthesia, to facilitate endotracheal intubation, and provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in all ages); to facilitate rapid sequence intubation (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219106\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zemuron may be confused with Remeron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219104\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Increased peripheral vascular resistance (abdominal aortic surgery: 24%, frequency not defined during other procedures), tachycardia (&le;5%; incidence greater in children), hypertension, transient hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylactoid reaction, asthma, cardiac arrhythmia, ECG abnormality, hiccups, injection site edema, nausea, vomiting </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219057\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to rocuronium, other neuromuscular-blocking agents, or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219041\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use is contraindicated in patients with previous anaphylactic reactions to other neuromuscular blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged paralysis: Some patients may experience prolonged recovery of neuromuscular function after administration (especially after prolonged use). Patients should be adequately recovered prior to extubation. Other factors associated with prolonged recovery should be considered (eg, corticosteroid use, patient condition).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Burn injury: Resistance may occur in burn patients (&ge;20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure); onset of action may be delayed and duration of action may be prolonged. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions that may <i>antagonize</i> neuromuscular blockade: Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Murray, 2002; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions that may <i>potentiate</i> neuromuscular blockade: Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), cachexia, neuromuscular diseases, metabolic acidosis, metabolic alkalosis,  respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary hypertension:  Use with caution in patients with pulmonary hypertension; use may increase pulmonary vascular resistance worsening symptoms of right heart failure. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Valvular heart disease: Use with caution in patients with valvular heart disease; use may increase pulmonary vascular resistance.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&bull; Corticosteroids: In addition to prolonging recovery from neuromuscular blockade, concomitant use with corticosteroids has been associated with development of acute quadriplegic myopathy syndrome (AQMS). Current guidelines recommend neuromuscular blockers be discontinued as soon as possible in patients receiving corticosteroids or interrupted daily until necessary to restart them based on clinical condition (Murray, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&bull; High potential for interactions: Numerous drugs either <i>antagonize</i> (eg, acetylcholinesterase inhibitors) or <i>potentiate</i> (eg, calcium channel blockers, certain antimicrobials, inhalation anesthetics, lithium, magnesium salts, procainamide, and quinidine) the effects of neuromuscular blockade; use with caution in patients receiving these agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly, effects and duration are more variable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immobilized patients: Resistance may occur in patients who are immobilized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Not recommended by the manufacturer for rapid sequence intubation in pediatric patients; however, it has been used successfully in clinical trials for this indication (Cheng, 2002; Fuchs-Buder, 1996; Mazurek, 1998; Naguib, 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical.  Rocuronium does not relieve pain or produce sedation; use should include appropriate anesthesia, pain control, and sedation. In patients requiring long-term administration in the ICU, tolerance to rocuronium may develop; use of a peripheral nerve stimulator to monitor drug effects is strongly recommended. Additional doses of rocuronium or any other neuromuscular-blocking agent should be avoided unless definite excessive response to nerve stimulation is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: If extravasation occurs, local irritation may ensue; discontinue administration immediately and restart in another vein.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300012\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219045\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12774&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Neuromuscular-Blocking Agents may diminish the therapeutic effect of Amifampridine. Amifampridine may diminish the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): May enhance the therapeutic effect of Rocuronium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219047\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219060\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Rocuronium crosses the placenta; umbilical venous plasma levels are ~18% of the maternal concentration following a maternal dose of 0.6 mg/kg  (Abouleish, 1994). The manufacturer does not recommend use for rapid sequence induction during cesarean section.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061876\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Peripheral nerve stimulator measuring twitch response, heart rate, blood pressure, assisted ventilation status</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219040\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219056\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &ge;3 months and Children: 30 seconds to 1 minute </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Good intubation conditions within 1 to 2 minutes (depending on dose administered); maximum neuromuscular blockade within 4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 3 to 12 months: 40 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 1 to 12 years: 26 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~30 minutes (with standard doses, increases with higher doses and inhalational anesthetic agents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 0.21 to 0.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 0.22 to 0.26 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hepatic dysfunction: 0.53 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal dysfunction: 0.34 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic; 17-desacetylrocuronium (5% to 10% activity of parent drug) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alpha elimination: 1 to 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Beta elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 3 to 12 months: 1.3 &plusmn; 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to &lt;3 years: 1.1 &plusmn; 0.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 3 to &lt;8 years: 0.8 &plusmn; 0.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 1.4 to 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hepatic impairment: 4.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal impairment: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (31%); urine (26%) (Proost 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Pediatric patients: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 3 to &lt;12 months: 0.35 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to &lt;3 years: 0.32 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 3 to &lt;8 years: 0.44 L/kg/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323798\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rocuronium Bromide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $4.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/10 mL (10 mL): $8.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Rocuronium Bromide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $9.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219061\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Curionialis (MX);</li>\n      <li>Desproxyl (MX);</li>\n      <li>Eslax (JP);</li>\n      <li>Esmeron (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, LY, MT, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, UA, VE, VN, YE);</li>\n      <li>Kabiroc (ID);</li>\n      <li>Rocum (ID);</li>\n      <li>Rocumeron (KR);</li>\n      <li>Rocur (UY);</li>\n      <li>Rocuron (BD);</li>\n      <li>Rocuronio (CO);</li>\n      <li>Romeron (KR);</li>\n      <li>Zemuron (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abouleish E, Abboud T, Lechevalier T, et al, &quot;Rocuronium (Org 9426) for Caesarean Section,&quot;  <i>Br J Anaesth</i>, 1994, 73(3):336-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/7946860/pubmed\" target=\"_blank\" id=\"7946860\">7946860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barclay K, Eggers K, Asai T. Low-dose rocuronium improves conditions for tracheal intubation after induction of anaesthesia with propofol and alfentanil. <i>Br J Anaesth</i>. 1997;78(1):92-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/9059214 /pubmed\" target=\"_blank\" id=\"9059214 \">9059214 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng CA, Aun CST, and Gin T, &quot;Comparison of Rocuronium and Suxamethonium for Rapid Tracheal Intubation in Children,&quot; <i>Paediatr Anaesth</i>, 2002, 12(2):140-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/11882225/pubmed\" target=\"_blank\" id=\"11882225\">11882225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs-Buder T and Tassonyi E, &quot;Intubating Conditions and Time Course of Rocuronium-Induced Neuromuscular Block in Children,&quot; <i>Br J Anaesth</i>, 1996, 77(3):335-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/8949805/pubmed\" target=\"_blank\" id=\"8949805\">8949805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaszynski TM, Szewczyk T. Rocuronium for rapid sequence induction in morbidly obese patients: a prospective study for evaluation of intubation conditions after administration 1.2 mg kg&#8315;&sup1; ideal body weight of rocuronium. <i>Eur J Anaesthesiol</i>. 2011;28(8):609-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/21562423 /pubmed\" target=\"_blank\" id=\"21562423 \">21562423 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? <i>Crit Care Med</i>. 2013;41(5):1332-1344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/23591211/pubmed\" target=\"_blank\" id=\"23591211\">23591211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han TH and Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus.<i>Br J Anaesth</i>. 2009, 102(1):55-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/19029093/pubmed\" target=\"_blank\" id=\"19029093\">19029093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan RF, Uejima T, Lobel G, et al, &ldquo;Intramuscular Rocuronium in Infants and Children: A Multicenter Study to Evaluate Tracheal Intubating Conditions, Onset, and Duration of Action,&rdquo; <i>Anesthesiology</i>, 1999, 91(3):633-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/10485771/pubmed\" target=\"_blank\" id=\"10485771\">10485771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ; Committee on Fetus and Newborn, Section on Anesthesiology and Pain Medicine. Premedication for nonemergency endotracheal intubation in the neonate. <i>Pediatrics</i>. 2010;125(3):608-615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/20176672 /pubmed\" target=\"_blank\" id=\"20176672 \">20176672 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JJ and Rubin AP, &quot;Breast Feeding and Anaesthesia,&quot; <i>Anaesthesia</i>, 1993, 48(7):616-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/8346780/pubmed\" target=\"_blank\" id=\"8346780\">8346780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leykin Y, Pellis T, Lucca M, et al, &quot;The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients,&quot; <i>Anesth Analg</i>, 2004, 99(4):1086-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/15385355/pubmed\" target=\"_blank\" id=\"15385355\">15385355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo; <i>Crit Care Med</i>, 1999, 27(7):1358-68. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/10446832/pubmed\" target=\"_blank\" id=\"10446832\">10446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mazurek AJ, Rae B, Hann S, et al, &quot;Rocuronium Versus Succinylcholine: Are They Equally Effective During Rapid-Sequence Induction of Anesthesia?&quot; <i>Anesth Analg</i>, 1998, 87:1259-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/9842809/pubmed\" target=\"_blank\" id=\"9842809\">9842809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo; <i>Crit Care Med</i>, 2002, 30(1):142-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/11902255/pubmed\" target=\"_blank\" id=\"11902255\">11902255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naguib M, Samarkandi AH, Ammar A, et al, &quot;Comparison of Suxamethonium and Different Combinations of Rocuronium and Mivacurium for Rapid Tracheal Intubation in Children,&quot; <i>Br J Anaesth</i>, 1997, 79(4):450-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/9389261/pubmed\" target=\"_blank\" id=\"9389261\">9389261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. <i>Paediatr Anaesth</i>. 2007;17(9):881-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/17683408 /pubmed\" target=\"_blank\" id=\"17683408 \">17683408 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds LM, Lau M, Brown R, et al, &ldquo;Bioavailability of Intramuscular Rocuronium in Infants and Children,&rdquo; <i>Anesthesiology</i>, 1997, 87(5):1096-105. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/9366462/pubmed\" target=\"_blank\" id=\"9366462\">9366462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocuronium injection [prescribing information]. Parsippany, NJ: The Medicines Company; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. <i>Ann Pharmacother</i>. 1996;30(2):165-172. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/8835051 /pubmed\" target=\"_blank\" id=\"8835051 \">8835051 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sparr HJ, Wierda JM, Proost JH, Keller C, Khuenl-Brady KS. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients.<i> Br J Anaesth</i>. 1997;78(3):267-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/9135303 /pubmed\" target=\"_blank\" id=\"9135303 \">9135303 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD. Continuous infusion of rocuronium in a paediatric intensive care unit. <i>Can J Anaesth</i>. 1996;43(4):353-357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/8697549 /pubmed\" target=\"_blank\" id=\"8697549 \">8697549 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warr J, Thiboutot Z, Rose L, Mehta S, Burry LD. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. <i>Ann Pharmacother</i>. 2011;45(9):1116-1126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-pediatric-drug-information/abstract-text/21828347 /pubmed\" target=\"_blank\" id=\"21828347 \">21828347 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willets LS, &ldquo;Rocuronium for Tracheal Intubation,&rdquo; <i>Ped Pharmacotherapy</i>, 2000, 6(10):1-6.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12774 Version 118.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F219069\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F219070\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061877\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445026\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061870\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F219051\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F219037\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061880\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F219067\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061879\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F219106\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F219104\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F219057\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F219041\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300012\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F219045\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F219047\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F219060\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061876\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F219040\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F219056\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323798\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F219061\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12774|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rocuronium-drug-information\" class=\"drug drug_general\">Rocuronium: Drug information</a></li><li><a href=\"topic.htm?path=rocuronium-patient-drug-information\" class=\"drug drug_patient\">Rocuronium: Patient drug information</a></li></ul></div></div>","javascript":null}